Why is Cancer Drug Discovery So Difficult?

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2006 Dec 13

PMID 17159925

Citations 114

Authors

Alexander Kamb

Susan Wee

Christoph Lengauer

Affiliations

Soon will be listed here.

Abstract

Thirty-five years after the 'war on cancer' was declared, the discovery of anticancer drugs remains a highly challenging endeavour. Here, we consider the factors responsible, such as tumour heterogeneity, and suggest strategies to improve the chances of short-term success in the development of novel anticancer drugs.

Citing Articles

Targeting cyclin-dependent kinase 11: a computational approach for natural anti-cancer compound discovery.

Bhambri S, Jha P Mol Divers. 2025; .

PMID: 39847188 DOI: 10.1007/s11030-025-11107-8.

Cardiovascular Tissue Engineering Models for Atherosclerosis Treatment Development.

Tscheuschner L, Tzafriri A Bioengineering (Basel). 2023; 10(12).

PMID: 38135964 PMC: 10740643. DOI: 10.3390/bioengineering10121373.

Evaluating the Activity and Safety of Modified LfcinB Peptides as Potential Colon Anticancer Agents: Cell Line Studies and Insect-Based Toxicity Assessments.

Cardenas-Martinez K, Barragan-Cardenas A, de la Rosa-Arbelaez M, Parra-Giraldo C, Ochoa-Zarzosa A, Lopez-Meza J ACS Omega. 2023; 8(41):37948-37957.

PMID: 37867694 PMC: 10586019. DOI: 10.1021/acsomega.3c03455.

Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review.

Mui M, Clark M, Vu T, Clemons N, Hollande F, Roth S Langenbecks Arch Surg. 2023; 408(1):392.

PMID: 37816905 PMC: 10564805. DOI: 10.1007/s00423-023-03133-7.

Brevilin A exerts anti-colorectal cancer effects and potently inhibits STAT3 signaling .

Meng M, Tan J, Chen H, Shi Z, Kwan H, Su T Heliyon. 2023; 9(8):e18488.

PMID: 37593607 PMC: 10432182. DOI: 10.1016/j.heliyon.2023.e18488.